Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Hypertension. 2021 Jul 12;78(3):851–858. doi: 10.1161/HYPERTENSIONAHA.121.17308

Table 1.

Baseline characteristics of the study cohort

Characteristic n=816
Age, years 70.8±9.0
Male sex 325 (39.8%)
Race
 White 102 (12.5%)
 Black 129 (15.8%)
 Hispanic 570 (69.9%)
 Others 15 (1.8%)
Hypertension 638 (78.2%)
Number of antihypertensive drugs (n=630)
 0 192 (30.5%)
 1 208 (33.0%)
 2 164 (26.0%)
 3 57 (9.1%)
 4 9 (1.4%)
Antihypertensive drug class
 ACEi/ ARB (n=659) 238 (36.1%)
 Beta-blocker (n=816) 206 (25.3%)
 Calcium channel blocker (n=650) 230 (35.4%)
 Diuretics (n=648) 167 (25.8%)
Hypercholesterolemia 559 (68.5%)
Diabetes mellitus 240 (29.4%)
Body mass index, kg/m2 28.3±4.8
Coronary artery disease 50 (6.1%)
Cigarette smoking 430 (52.7%)
eGFR, mL/min/1.73m2 (n=790) 73.9±18.3
Atrial fibrillation 50 (6.1%)
Education
 8th grade or less 331 (40.6%)
 some high school 122 (15.0%)
 completed high school 115 (14.1%)
 some college 117 (14.3%)
 college graduate or more 131 (16.1%)
Office BP variables
 Office SBP, mm Hg 135.6±17.7
 Office DBP, mm Hg, 78.6±9.4
 Office PP, mm Hg 57.0±14.8
Central BP variables
 Central SBP, mm Hg 119.5±18.9
 Central DBP, mm Hg 72.1±10.2
 Central PP, mm Hg 47.4±15.3
Ambulatory BP variables
 24-h SBP, mm Hg 124.8±14.4
 24-h DBP, mm Hg 71.4±8.6
 24-h PP, mm Hg 53.5±11.2
 Daytime SBP, mm Hg 128.2±14.5
 Daytime DBP, mm Hg 74.2±9.0
 Daytime PP, mm Hg 54.0 ±11.3
 Nighttime SBP, mm Hg 118.7±16.3
 Nighttime DBP, mm Hg 66.1±9.4
 Nighttime PP, mm Hg 52.6±11.9

Values are mean±standard deviation or n (percentage). ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; PP, pulse pressure; SBP. systolic blood pressure.